B. Besse 1, ⁎ , A.E. Drillon 2, B.J. Solomon 3, V. Subbiah 4, D. Shao-Weng Tan 5, K. Park 6, F.G. De Braud 7, G. Alonso 8, J. Wolf 9, V. Soldatenkova 10, A.K. Lin 10, P. Plernjit French 10, K. goto 11, O. Gautschi 12
1 Institut Gustave Roussy et Université Paris-Sud, Paris, France
2 Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, États-unis
3 Department of Medical Oncology and Research Division, Peter MacCallum Cancer Centre et Sir Peter MacCallum Department of Oncology, Université de Melbourne, Melbourne, Australie
4 Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, États-unis
5 National Cancer Center, Singapour, Singapour
6 Division of Hematology/Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Séoul, République populaire démocratique de Corée
7 Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italie
8 Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Hospital Universitari, Barcelone, Espagne
9 Department of Internal Medicine, Center for Integrated Oncology, University Hospital Cologne, Cologne, Allemagne
10 Eli Lilly and Company, Indianapolis, États-unis
11 National Cancer Center Hospital East, Kashiwa, Japon
12 Université de Berne et hôpital cantonal de Lucerne, Lucerne, Suisse